TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15730434

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg) and herbal ephedra (20 mg ephedrine)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 14642668

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shock waves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iontophoresis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short waves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microwaves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infrasound vibrations
Number of subjects: 0
Study: 10908688

Group type: EXPERIMENTAL
Intervention: Homeopathic gel
Number of subjects: 184

Group type: COMPARATOR
Intervention: Piroxicam gel
Number of subjects: 184
Study: 8621147

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 0
Study: 1462402

Group type: EXPERIMENTAL
Intervention: Diltiazem (n = 12, 240-360 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Verapamil (n = 12, 240-360 mg)
Number of subjects: 24
Study: 3931216

Group type: EXPERIMENTAL
Intervention: misoprostol 200 micrograms daily
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: misoprostol 800 micrograms daily
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: cimetidine 1200 mg daily
Number of subjects: 119
Study: 31654188

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 350
Study: 30610771

Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic education
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual diabetes education (Control)
Number of subjects: 130
Study: 26364833

Group type: EXPERIMENTAL
Intervention: McDonald cerclage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate (17OHP‐C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 90
Study: 24832974

Group type: EXPERIMENTAL
Intervention: CIVE
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: VIVE
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CICE
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: VICE
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 49
Study: 22652933

Group type: EXPERIMENTAL
Intervention: Activity intervention
Number of subjects: 128
Study: 20594468

Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Normal saline)
Number of subjects: 20
Study: 18325056

Group type: EXPERIMENTAL
Intervention: Darifenacin controlled-release 7.5 mg
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Darifenacin controlled-release 15 mg
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study: 15983452

Group type: EXPERIMENTAL
Intervention: Propofol (moderate sedation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propofol (deep sedation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12466781

Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg) administered to patients showing signs of fatigue before reaching minimal HR (group A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (group B) who spontaneously achieved minimal HR
Number of subjects: 108

Group type: COMPARATOR
Intervention: Comparison of perfusion studies between group A and group B
Number of subjects: 108
Study: 10728909

Group type: EXPERIMENTAL
Intervention: Intravenous etoposide 150 mg/M2
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Intravenous etoposide 150 mg/M2 with mannitol 15 gm/M2
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low grade astrocytomas
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Medulloblastoma or PNET
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High grade astrocytomas
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Brain stem gliomas
Number of subjects: 99
Study: 7493659

Group type: EXPERIMENTAL
Intervention: Dairy foods group (n = 81) consuming approximately 30 grams of dairy protein daily
Number of subjects: 158

Group type: COMPARATOR
Intervention: Dairy-free diet group (n = 77) eating no dairy foods
Number of subjects: 158
Study: 2268021

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 50 micrograms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 100 micrograms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% plain
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% with fentanyl 50 micrograms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% with fentanyl 100 micrograms
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 100
Study: 6787694

Group type: EXPERIMENTAL
Intervention: Intravenous pirenzepine 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 0
Study: 30739210

Group type: EXPERIMENTAL
Intervention: 3D image group
Number of subjects: 71

Group type: COMPARATOR
Intervention: two‐dimensional computed tomography (CT) group
Number of subjects: 71
Study: 28931011

Group type: EXPERIMENTAL
Intervention: Central information highlighting flaws in the expert’s message (e.g., quality of the research presented by the expert)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peripheral information about the expert (e.g., credentials)
Number of subjects: 0
Study: 25400242

Group type: EXPERIMENTAL
Intervention: Telemedicine care
Number of subjects: 101

Group type: COMPARATOR
Intervention: Traditional outpatient visits (Control)
Number of subjects: 101
Study: 22429008

Group type: EXPERIMENTAL
Intervention: Corega Extradent for 5 min
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Corega Extradent for 8 h
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: NitrAdine™ Seniors for 15 min
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: NaOCl 5.25%
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 35
Study: 21601480

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 138

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 138
Study: 18655272

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia
Number of subjects: 108
Study: 17031011

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis (BB‐12)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (ATCC 55730)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Probiotics-free formula
Number of subjects: 59
Study: 12919340

Group type: EXPERIMENTAL
Intervention: Antiepileptic treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 0
Study: 10675381

Group type: EXPERIMENTAL
Intervention: ATP treatment (10 intravenous 30-hour infusions at 2- to 4-week intervals)
Number of subjects: 58
Study: 9308747

Group type: EXPERIMENTAL
Intervention: Aprotinin therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 8121306

Group type: EXPERIMENTAL
Intervention: Arginine (ARG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lipid-heparin infusion (Control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GHRH + Arginine (ARG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lipid-heparin infusion (Control) + Arginine (ARG)
Number of subjects: 14
Study: 2518866

Group type: EXPERIMENTAL
Intervention: 50-micrograms SMS 201-995
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100-micrograms SMS 201-995
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 869026

Group type: EXPERIMENTAL
Intervention: Unlimited alcohol and/or cigarettes during the second week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Abstinence from alcohol and cigarettes during the first week
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Measures of affect (hostility/aggression)
Number of subjects: 40
Study: 31843372

Group type: EXPERIMENTAL
Intervention: MFCLs with +2.0 D (Add2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MFCLs with +4.0 D (Add4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single vision lenses (SVCL; Add0)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MFCLs with +2.0 D (Add2) and +4.0 D (Add4)
Number of subjects: 24
Study: 31421094

Group type: EXPERIMENTAL
Intervention: Autotitrating CPAP for OSA for 3 months
Number of subjects: 79
Study: 27615793

Group type: EXPERIMENTAL
Intervention: Active bilateral prefrontal rTMS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study: 26125769

Group type: EXPERIMENTAL
Intervention: emergency PCI + rhBNP early treatment (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: emergency PCI + late rhBNP treatment (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: emergency PCI (Group A)
Number of subjects: 90
Study: 24299712

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus CGMCC1.3724 (LPR) supplementation (1.6 × 10(8) colony-forming units of LPR/capsule, 2 capsules per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus CGMCC1.3724 (LPR) supplementation
Number of subjects: 0
Study: 22990514

Group type: EXPERIMENTAL
Intervention: Intensive outpatient therapy including mechanical lymph drainage using the RAGodoy® apparatus for 6 to 8 hours daily, Godoy & Godoy cervical stimulation technique for 20 minutes per day, and manual lymph drainage for one hour.
Number of subjects: 8
Study: 19174453

Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND arm)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy (SLNB arm)
Number of subjects: 225
Study: 17443402

Group type: EXPERIMENTAL
Intervention: Sensory focus
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study: 15082123

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 11334123

Group type: EXPERIMENTAL
Intervention: Montelukast (Cys-LT1 antagonist)
Number of subjects: 1500
Study: 9127642

Group type: EXPERIMENTAL
Intervention: Cytokine expression measured via semi-quantitative RT-PCR for IFN gamma, IL-1 beta, IL-4, and IL-6
Number of subjects: 0
Study: 1541492

Group type: EXPERIMENTAL
Intervention: Synthetic splinting materials (water-activated polyurethanes, thermoplastic)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Plaster-of-Paris
Number of subjects: 203
Study: 2421622

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) therapy for 1 week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) therapy
Number of subjects: 12
Study: 30411596

Group type: EXPERIMENTAL
Intervention: Soccer training (4 extra sessions per week)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (physical fitness sessions at school)
Number of subjects: 56
Study: 29411446

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) during hospitalisation
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) post-discharge
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: NRT use during hospitalisation for heavy smokers
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: NRT use post-discharge for heavy smokers
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: NRT use during hospitalisation for those using six or more medications
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: NRT use post-discharge for patients admitted for respiratory or cardiac problems
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: NRT use during hospitalisation when offered free of cost
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: NRT use prediction by nicotine dependence
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: NRT use prediction by interest in using NRT
Number of subjects: 600
Study: 27457914

Group type: EXPERIMENTAL
Intervention: Inertial Training (T0 group, 19.4 kg flywheel)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Inertial Training (T10 group, 29.4 kg flywheel)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 24723432

Group type: EXPERIMENTAL
Intervention: venlafaxine Extended‐Release (XR) treatment
Number of subjects: 156
Study: 22178393

Group type: EXPERIMENTAL
Intervention: 40 mg orally administered hydrocortisone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study: 20334583

Group type: EXPERIMENTAL
Intervention: NuvaRing (various regimens: 21/7, 42/7, 84/7, 357/7)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: NuvaRing (various regimens)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: NuvaRing (longer regimens)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no contraception)
Number of subjects: 109
Study: 17363530

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (0.125 or 0.250 mg/kg), bortezomib (0.7, 1.0, or 1.3 mg/m(2)), ascorbic acid (1 g) i.v. on days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bortezomib (0.7 mg/m(2))
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.0 or 1.3 mg/m(2))
Number of subjects: 22
Study: 15784480

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (ProViva) in addition to conventional therapy (treatment group, n = 52)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional therapy alone (control group, n = 51)
Number of subjects: 103
Study: 11994835

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 91
Study: 9862242

Group type: EXPERIMENTAL
Intervention: Acidification of urine pH, low urinary flow (Regimen A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acidification of urine pH, high urinary flow (Regimen B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alkalinization of urine pH, low urinary flow (Regimen C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alkalinization of urine pH, high urinary flow (Regimen D)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regimens A and B (acidic urine pH)
Number of subjects: 12
Study: 7615313

Group type: EXPERIMENTAL
Intervention: MkII implant
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard Brånemark System implant
Number of subjects: 103
Study: 2262234

Group type: EXPERIMENTAL
Intervention: MPA-B (methyl prednisolone acetate with bupivacaine)
Number of subjects: 56

Group type: COMPARATOR
Intervention: MPA-L (methyl prednisolone acetate with lidocaine)
Number of subjects: 56
Study: 7392402

Group type: EXPERIMENTAL
Intervention: Physical training for one year, including therapeutical physical exercises, dosaged running, elements of sport games, and training on a bicycle ergometer
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 75
Study: 31633865

Group type: EXPERIMENTAL
Intervention: 40 mg controlled-release oral morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30001503

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training with blood flow restriction (RT-BFR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28566024

Group type: EXPERIMENTAL
Intervention: MePrEPA (four-week group psychoeducational intervention)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Parent-support control group
Number of subjects: 172
Study: 26558994

Group type: EXPERIMENTAL
Intervention: Single CT scan assessment of bone mineral density, vascular calcification and fat mass
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Single CT scan assessment of body composition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: QCT analysis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: DXA analysis
Number of subjects: 64
Study: 23180154

Group type: EXPERIMENTAL
Intervention: α‐Lipoic acid (1,200 mg d(‐1) for 10 days)
Number of subjects: 16
Study: 21506207

Group type: EXPERIMENTAL
Intervention: Problem Solving Education (PSE)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control
Number of subjects: 93
Study: 18793232

Group type: EXPERIMENTAL
Intervention: Muscular counterpulsation (MCP) treatment for 30 minutes daily for the first eight postoperative days in addition to standard therapy.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard postoperative treatment without counterpulsation (control group).
Number of subjects: 50
Study: 17382730

Group type: EXPERIMENTAL
Intervention: Vaccine plus boosters
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 75
Study: 15042664

Group type: EXPERIMENTAL
Intervention: Tumor size, lymph node status, and tumor grade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox regression model with time‐varying coefficients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frailty models
Number of subjects: 0
Study: 11573587

Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 mg ml(-1) with glucose 8 mg ml(-1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine 5 mg ml(-1) with glucose 80 mg ml(-1)
Number of subjects: 40
Study: 9784073

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg/70 kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7821012

Group type: EXPERIMENTAL
Intervention: Barrier cream
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Afterwork emollient cream
Number of subjects: 3

Group type: COMPARATOR
Intervention: No cream (controls)
Number of subjects: 3
Study: 3392230

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31563660

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20 g/day for 1 week, then 5 g/day for 7 weeks)
Number of subjects: 29
Study: 31537373

Group type: EXPERIMENTAL
Intervention: Multivitamin multimineral supplement
Number of subjects: 3983

Group type: COMPARATOR
Intervention: Iron and folate
Number of subjects: 3983

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 3983

Group type: COMPARATOR
Intervention: No co-trimoxazole
Number of subjects: 3983
Study: 28130378

Group type: EXPERIMENTAL
Intervention: Continuous treatment with the NOAC apixaban
Number of subjects: 650

Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) therapy
Number of subjects: 650
Study: 26289478

Group type: EXPERIMENTAL
Intervention: Isokinetic (IK) training
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dynamic Constant External Resistance (DCER) training
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 24448329

Group type: EXPERIMENTAL
Intervention: Zinc sulfate 220 mg daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20234136

Group type: EXPERIMENTAL
Intervention: 12 mg betamethasone in a single dose (group 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (group 1, no betamethasone)
Number of subjects: 100
Study: 18359663

Group type: EXPERIMENTAL
Intervention: PEG-IFN alpha-2b treatment
Number of subjects: 123
Study: 16091926

Group type: EXPERIMENTAL
Intervention: Microperimeter 1 (MP‐1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Scanning Laser Ophthalmoscope (SLO)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison of MP‐1 and SLO
Number of subjects: 31
Study: 12823591

Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg/day) for 104 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg/day) for 104 weeks with or without 4 months of interferon (IFN) combination
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: In vitro transfection studies
Number of subjects: 31
Study: 10607275

Group type: EXPERIMENTAL
Intervention: Student-led PBL groups
Number of subjects: 127

Group type: COMPARATOR
Intervention: Faculty-led PBL groups
Number of subjects: 127
Study: 9010561

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with modified phleum pratense allergenic extracts
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not treated with specific IT, only with drugs)
Number of subjects: 10
Study: 1379739

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (600 LRU daily for 24 weeks)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 6360832

Group type: EXPERIMENTAL
Intervention: Calcium-vitamin-D-combination (single dose ampoules for peroral application)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31782265

Group type: EXPERIMENTAL
Intervention: Resonance Frequency (RF) breathing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RF + 1 breaths per minute
Number of subjects: 10

Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB)
Number of subjects: 10
Study: 29989855

Group type: EXPERIMENTAL
Intervention: Isolated nodal infradiaphragmatic disease
Number of subjects: 223

Group type: COMPARATOR
Intervention: Supradiaphragmatic disease
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Infradiaphragmatic HL
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (ABVD and BEACOPPescalated)
Number of subjects: 223
Study: 26854042

Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee arthroplasty (MB)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Fixed-bearing total knee arthroplasty (FB)
Number of subjects: 93